|
Indian pharmaceutical companies are supporting the recent US FDA guidance on safety reporting requirements for Bioavailability (BA) and Bioequivalence (BE) studies. The new guidelines are seen as a significant step toward enhancing the safety and transparency of clinical trials, particularly in the context of generic drug development.
With a growing number of Indian companies conducting BA/BE studies to support the approval of generic drugs in global markets, the updated safety reporting framework is expected to streamline processes and improve compliance with international regulatory standards. The move is being hailed as a win-win for both patient safety and the global competitiveness of Indian pharma.
Industry noted that BA/BE evaluation is crucial for demonstrating a drug’s consistency, safety, and clinical efficacy, especially for generics and modified formulations. In fact, India, and Karnataka particularly, organised a one-day workshop in November end. It was hosted by the Indian Pharmaceutical Association-Karnataka State (IPA-KTK) branch and the Karnataka Drugs and Pharmaceutical Manufacturers Association (KDPMA) to address on ‘BA/BE: Managing Regulatory Changes in Solid Oral Dosage Forms.’
Titled as the guidance of Bioavailability and Bioequivalence Studies and Safety Assessment for IND and for Industry by US FDA, it provides recommendations to help sponsors comply with the expedited safety reporting requirements. This is for human drug and biological products that are being investigated under an investigational new drug application or as part of a BA or BE study that is exempt from the IND requirements.
This guidance, US FDA said, provides interpretations of terms used for safety reporting, makes recommendations on when and how to submit a safety report, and provides information on other safety reporting issues raised by sponsors. To facilitate appropriate IND safety reporting practices, this guidance also provides recommendations related to the two IND safety reporting provisions.
With regard to the content from the 2012 final guidance that was incorporated into this guidance, a considerable amount remains unchanged. However, this guidance includes updated recommendations on submissions of IND safety reports and replaces the 2012 final guidance in terms of sponsors’ responsibilities for safety reporting requirements for INDs and BA/BE studies.
This guidance does not incorporate content on investigator reporting from the 2012 final guidance. Concurrent with the publication of this guidance, FDA issued the guidance for investigators, industry, and institutional review boards on Investigational Drugs and Devices in this month on the responsibilities for investigators about adverse event reporting that replaces the corresponding recommendations for investigators in the 2012 final guidance. Accordingly, the 2012 final guidance was withdrawn upon the publication of these two guidance. This guidance addresses reporting of serious adverse events (SAEs) in the setting of a clinical investigation conducted under an IND. Drugs used in such clinical investigations may be unapproved drugs or those that are already marketed or approved in the United States, said US FDA.
|